- Home
- FONR vs CHRS Comparison
FONR vs CHRS Comparison
Compare FONR & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FONR
- CHRS
- Stock Information
- Founded
- FONR 1978
- CHRS 2010
- Country
- FONR United States
- CHRS United States
- Employees
- FONR N/A
- CHRS N/A
- Industry
- FONR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FONR Health Care
- CHRS Health Care
- Exchange
- FONR Nasdaq
- CHRS Nasdaq
- Market Cap
- FONR 99.1M
- CHRS 100.9M
- IPO Year
- FONR 1987
- CHRS 2014
- Fundamental
- Price
- FONR $15.03
- CHRS $0.74
- Analyst Decision
- FONR
- CHRS Strong Buy
- Analyst Count
- FONR 0
- CHRS 4
- Target Price
- FONR N/A
- CHRS $6.13
- AVG Volume (30 Days)
- FONR 20.9K
- CHRS 2.7M
- Earning Date
- FONR 11-12-2024
- CHRS 11-06-2024
- Dividend Yield
- FONR N/A
- CHRS N/A
- EPS Growth
- FONR N/A
- CHRS N/A
- EPS
- FONR 1.42
- CHRS N/A
- Revenue
- FONR $102,006,089.00
- CHRS $304,340,000.00
- Revenue This Year
- FONR N/A
- CHRS $3.33
- Revenue Next Year
- FONR N/A
- CHRS $16.77
- P/E Ratio
- FONR $10.57
- CHRS N/A
- Revenue Growth
- FONR 0.70
- CHRS 44.19
- 52 Week Low
- FONR $14.05
- CHRS $0.66
- 52 Week High
- FONR $24.05
- CHRS $3.70
- Technical
- Relative Strength Index (RSI)
- FONR 43.59
- CHRS 39.72
- Support Level
- FONR $14.78
- CHRS $0.77
- Resistance Level
- FONR $16.02
- CHRS $0.89
- Average True Range (ATR)
- FONR 0.48
- CHRS 0.08
- MACD
- FONR 0.06
- CHRS 0.01
- Stochastic Oscillator
- FONR 35.80
- CHRS 28.47
About FONR Fonar Corporation
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.